<DOC>
	<DOCNO>NCT02280603</DOCNO>
	<brief_summary>This study design explore efficacy safety DA-4001 topical application male patient androgenetic alopecia Design : Randomized , double-blind , active-controlled study Investigational Product : Finasteride , minoxidil</brief_summary>
	<brief_title>Clinical Trial Explore Efficacy Safety DA-4001 After Topical Application</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Basic specific ( BASP ) classification : basic type M2 C2 specific type V1 , V2 F1 , F2 Evidence hair loss androgenetic alopecia Use finasteride , dutasteride within previous 12 month Use minoxidil within previous 6 month Use androgenic antiandrogenic agent within previous 6 month Use steroid agent local application scalp systemic application within previous 1 month History hair transplantation , scalp reduction Coronary artery disease , arrhythmia , congestive heart failure , valvular haert disease , angina pectoris</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>